BioStem Technologies Q2 2025 Earnings Report

BioStem Technologies EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.32
• Beat/Miss: N/A
• One Year Ago EPS: N/A

BioStem Technologies Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $78.22 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

BioStem Technologies Announcement Details

• Quarter: Q2 2025
• Date: 8/11/2025
• Time: After Market Closes
• Conference Call Date: Monday, August 11, 2025
• Conference Call Time: 4:30PM ET

BioStem Technologies (OTCMKTS:BSEM) (OTCMKTS:BSEM) is a development‐stage biotechnology company dedicated to advancing regenerative medicine through innovative cell‐based and immuno‐oncology therapies. The company focuses on identifying and developing adult stem cell treatments and small‐molecule immunomodulators designed to enhance the body’s natural healing processes. Its research efforts aim to address a range of conditions, with a particular emphasis on cancer, chronic wounds and autoimmune disorders.

At the core of BioStem’s activities is a proprietary research platform that integrates patient‐derived cell lines with high‐throughput screening to discover novel therapeutic candidates. The company’s pipeline includes both preclinical and early‐stage assets, targeting tumor microenvironment modulation and tissue regeneration. Additionally, BioStem offers contract research services to academic and industry partners, leveraging its in-house expertise in cell culture, assay development and biomarker analysis.

Founded in the early 2000s and headquartered in Florida, BioStem Technologies operates research facilities in the United States while collaborating with academic and clinical centers across North America and Europe. The company has established partnerships for technology licensing and distribution to support future clinical trials and expand geographic reach. Through these alliances, BioStem aims to accelerate the translation of its laboratory discoveries into therapeutic applications and potential commercial products.

BioStem’s leadership team comprises seasoned executives and scientific experts with decades of combined experience in biotechnology development, regulatory affairs and corporate strategy. The board and management draw on backgrounds in cell therapy research, pharmaceutical development and finance, guiding the company through preclinical milestones and regulatory interactions. With a focus on innovation and rigorous scientific validation, BioStem Technologies continues to position itself at the forefront of regenerative medicine research.